- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00511069
Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
A Phase II Study of Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
Ph+ leukemias (i.e.Chronic Myelogenous Leukemia (CML) and (Ph+) Acute Lymphoblastic Leukemia are malignant clonal disorder of the hemopoietic stem cell due to reciprocal translocation of genetic material between chromosome 9 and 22 giving rise to the translocation t(9;22) (q2.2; q2.1). The translocation causes the formation of a new hybrid gene (bcr-abl) that codes for a 185 kb or 210 kb cytoplasmic protein (P185 and P210 respectively) that by autophosphorylation activates a number of signaling pathways involved in cell proliferation, maturation, apoptosis and adhesion, leading to the malignant cell transformation1-3. The course of the disease goes on through a chronic phase (CP), usually lasting some years, that is characterized by a massive myeloid hyperplasia with hyperleukocytosis and splenomegaly. The CP is almost always followed by an accelerated or blastic phase (ABP) where the leukemic process acquires the characteristics of acute leukemia. The ABP usually lasts some months and terminates with the death of the patient3.
The frequency of CML in western countries ranges between 10 and 15 per million persons (age - standardized). It is rare in children. The median age is 55 years.
Current treatment of CML includes conventional chemotherapy, allogeneic bone marrow transplantation (allo BMT), alpha-interferon (alpha-IFN)and imatinib.
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Bologna, Italien, 40138
- Policlinico "S.Orsola-Malpighi"-Istituto di Ematologia "L e A Seragnoli"
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria for chronic phase patients :
- Age >/=18 years
- Ph positive
- Absence of a CHR after 3 months on imatinib
- Loss of a previously obtained CHR on imatinib alone
- Absence of a CCgR within 12 months on imatinib alone
- Loss of a previously obtained CCgR on imatinib alone
- Written informed consent
Exclusion Criteria for chronic phase patients :
- Age <18
- Performance status (ECOG/WHO) > 2 (see Appendix 2)
- Inability to provide written informed consent
- Pregnancy
- Accelerated or blastic phase
- Formal refusal of any recommendation of a safe contraception
- Alcohol or drug addiction
- Altered hepatic or renal function as defined by AST/ALT or bilirubin > 3 times upper normal limits (UNL)
- Serum creatinine > 265 umol/l or >3.0 mg/dl
- Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.
Inclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia Ph+ patients:
- Age >/=18 years
- Ph positive
- Loss of a previous hematological response to imatinib alone, with further progression to ABP (see section 14 for definitions)
- Performance status (ECOG/WHO)
- Written informed consent
Exclusion criteria for accelerated and blastic phase or acute lymphoblastic leukemia Ph+ patients:
- Age <18
- Performance status (ECOG/WHO) > 2 (see Appendix 2)
- Inability to provide written informed consent
- Pregnancy
- Chronic Phase disease
- Formal refusal of any recommendation of a safe contraception
- Alcohol or drug addiction
- Altered hepatic or renal function as defined by AST/ALT or bilirubin > 3 times upper normal limits (UNL)
- Serum creatinine > 265 umol/l or >3.0 mg/dl
- Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Giovanni Martinelli, MD, Istituto di Ematologia "L e A Seragnoli" Policlinico S.Orsola-Malpighi di Bologna
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CML/033-26866138-CAN
- EUDRACT 2004-002977-22
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Bortezomib
-
The First Affiliated Hospital of Soochow UniversityUkendtMyelom påvist ved laboratorietestKina
-
Baylor College of MedicineMillennium Pharmaceuticals, Inc.AfsluttetProstata neoplasmerForenede Stater
-
NCIC Clinical Trials GroupAfsluttet
-
University Hospital, Clermont-FerrandLaboratoires TakedaUkendtMyelomatose | Voksen | Bortezomib-regimenFrankrig
-
National Cancer Institute (NCI)AfsluttetGastrointestinal kræft | Avanceret primær leverkræft hos voksne | Lokaliseret ikke-operabel primær leverkræft hos voksne | Tilbagevendende primær leverkræft hos voksne | Tilbagevendende ekstrahepatisk galdevejskræft | Tilbagevendende galdeblærekræft | Ikke-operabel ekstrahepatisk galdevejskræft | Ikke-operabel... og andre forholdForenede Stater
-
Janssen-Cilag International NVAfsluttetMyelomatoseKalkun, Grækenland, Tjekkiet, Østrig, Tyskland, Sverige, Det Forenede Kongerige, Danmark
-
University Health Network, TorontoNational Cancer Institute (NCI)AfsluttetBlærekræft | Overgangscellekræft i nyrebækkenet og urinlederenForenede Stater, Canada
-
Janssen Korea, Ltd., KoreaAfsluttet
-
Southwest Oncology GroupNational Cancer Institute (NCI)Afsluttet
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AfsluttetLymfom | Myelodysplastiske syndromer | Leukæmi | Myelom og plasmacelle-neoplasmaForenede Stater